Aquestive Therapeutics, Inc. (NASDAQ:AQST) Short Interest Up 8.6% in December

Aquestive Therapeutics, Inc. (NASDAQ:AQST) was the recipient of a large increase in short interest in December. As of December 31st, there was short interest totalling 10,480,000 shares, an increase of 8.6% from the December 15th total of 9,650,000 shares. Based on an average daily volume of 1,550,000 shares, the days-to-cover ratio is currently 6.8 days.

Aquestive Therapeutics Trading Up 0.3 %

NASDAQ:AQST opened at $3.10 on Tuesday. Aquestive Therapeutics has a 52 week low of $2.24 and a 52 week high of $6.23. The stock has a 50 day moving average of $3.93 and a 200-day moving average of $4.19. The firm has a market capitalization of $282.66 million, a PE ratio of -6.89 and a beta of 2.71.

Aquestive Therapeutics (NASDAQ:AQST) last issued its quarterly earnings data on Monday, November 4th. The company reported ($0.13) earnings per share for the quarter, missing the consensus estimate of ($0.12) by ($0.01). The company had revenue of $13.54 million for the quarter, compared to analysts’ expectations of $12.69 million. During the same quarter in the previous year, the company posted ($0.03) EPS. As a group, analysts predict that Aquestive Therapeutics will post -0.46 EPS for the current fiscal year.

Institutional Trading of Aquestive Therapeutics

Several hedge funds have recently added to or reduced their stakes in the business. Victory Capital Management Inc. acquired a new position in shares of Aquestive Therapeutics during the second quarter valued at $27,000. nVerses Capital LLC acquired a new stake in shares of Aquestive Therapeutics in the 3rd quarter worth approximately $28,000. The Manufacturers Life Insurance Company bought a new position in shares of Aquestive Therapeutics in the second quarter valued at approximately $76,000. Harvey Capital Management Inc. bought a new stake in Aquestive Therapeutics during the third quarter worth approximately $88,000. Finally, Intech Investment Management LLC acquired a new stake in Aquestive Therapeutics in the third quarter worth approximately $90,000. Institutional investors own 32.45% of the company’s stock.

Analyst Ratings Changes

A number of analysts recently issued reports on AQST shares. JMP Securities restated a “market outperform” rating and issued a $9.00 price target on shares of Aquestive Therapeutics in a research note on Tuesday, October 8th. HC Wainwright reissued a “buy” rating and issued a $10.00 target price on shares of Aquestive Therapeutics in a research report on Friday, December 20th. Leerink Partners increased their price target on shares of Aquestive Therapeutics from $12.00 to $13.00 and gave the stock an “outperform” rating in a research report on Friday, October 25th. Finally, Cantor Fitzgerald assumed coverage on Aquestive Therapeutics in a report on Tuesday, December 17th. They issued an “overweight” rating and a $17.00 price objective for the company. Six analysts have rated the stock with a buy rating and one has issued a strong buy rating to the company’s stock. According to MarketBeat, the stock presently has a consensus rating of “Buy” and an average target price of $11.00.

Aquestive Therapeutics Company Profile

Aquestive Therapeutics, Inc operates as a pharmaceutical company in the United States and internationally. The company markets Sympazan, an oral soluble film formulation of clobazam for the treatment of lennox-gastaut syndrome; Suboxone, a sublingual film formulation of buprenorphine and naloxone for the treatment of opioid dependence; Zuplenz, an oral soluble film formulation of ondansetron for the treatment of nausea and vomiting associated with chemotherapy and post-operative recovery; and Azstarys, a once-daily product for the treatment of attention deficit hyperactivity disorder.